All In Biotech

Drug Trial Radar · NCT07226895

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

A Study to Explore Changes in Cognitive, Clinical, Biological and Digital Measures Following 8 Weeks of Twice-daily Dosing of MT1988 and to Evaluate Safety & Tolerability of MT1988, in Participants at Clinical High Risk (CHR) for Psychosis

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 3, 2026

Primary completion

Sep 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Monument Therapeutics LimitedIndustry
Sponsor type
Industry
Collaborators
National Institute of Mental Health (NIMH); Foundation for the National Institutes of Health; Accelerating Medicines Partnership (AMP)
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 17 years, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks. This will help identify tests that could be used in later trials developing treatments for symptoms in people at high risk of developing psychosis, to measure whether those new treatments are effective. The main question this trial aims to answer is: Can any of the tests (biomarkers) used in this study detect changes in participants dosed with one of two different dose levels of MT1988? Researchers will compare the results from two dose levels of MT1988 to a placebo group. Researchers do not expect to see the test results change in participants taking placebo and this will be compared to changes expected in test results in participants taking MT1988. Participants will: * take a dose of MT1988 or placebo twice per day for 8 weeks * attend clinic appointments every two weeks to undertake assessments * report any side effects they experience to the researchers

Conditions

  • Clinical High Risk for Psychosis (CHR)

Interventions

  • MT1988 Low DoseDrug

    Oral dosing MT1988; dose level 1

  • MT1988 High DoseDrug

    Oral dosing MT1988; dose level 2

  • PlaceboDrug

    Oral Placebo; blinded to match MT1988 all doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to week 8 in test of verbal memory (List Learning Task) as measured by the Penn Computerized Neurobehavioral Battery (PennCNB) test batteryTime frame: Day 56
  2. Change from baseline to week 8 in attenuated positive symptoms as measured by PSYCHS-CT total scoreTime frame: Day 56
  3. Change from baseline to week 8 in negative symptoms as measured by the Negative Symptom Inventory - Psychosis Risk (NSI-PR) total scoreTime frame: Day 56

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Irvine

    Irvine, California · Recruiting

  • University of California

    Los Angeles, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Yale University Conneticut Mental Health Center

    New Haven, Connecticut · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Northwell Health

    Glen Oaks, New York · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • Icahan School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Prevention Science Institute

    Eugene, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Temple University

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh School of Medicine

    Pittsburgh, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.